India sees a big future for itself in biogenerics. Wockhardt, Dr Reddy's Lab, Biocon, Sun Pharma, Shanta Biotech, Panacea Biotech and Ranbaxy Lab are all initiating programs to develop biosimilars in anticipating of U.S. approval of a new regulatory pathway--at some point. Exactly what that point is, though, remains a mystery. Report